safety of compounded tirzepatide Weight Loss Program | GLP-1 Treatment September 2, 2025: U.S. compounding
Description
Some patients report better tolerance when injecting in the evening, as nausea, if it occurs, happens during sleep
Tirzepatide (Mounjaro) is a dual GLP-1 and GIP receptor agonist that reduces appetite and slows stomach emptying, helping your body feel full longer
But you should talk about these with your doctor to make sure it is safe, especially for long-term use
Abstract Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1) exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion
